"Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer"
Matthew Galsky, MD, Director of Genitourinary Medical Oncology at The Tisch Cancer Institute, examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring CPI in metastatic urothelial carcinoma (UC), this analysis demonstrated no statistically significant difference in response rates in patients with FGFR3-mutant versus wild-type UC. In this study, Dr. Galsky suggested that “Similar response rates may be explained by a balancing out of previously identified independent positive and negative predictors of CPI sensitivity compared with FGFR3 wild-type UC, FGFR3-mutant UC is associated with a similar tumor mutational burden, lower T-cell infiltration, but also lower stromal/transforming growth factor beta signals.”
— Matthew Galsky, MD, Director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai